OCBC: significantly raises Ganfeng Lithium Group (01772) target price to 83 Hong Kong dollars, increased profit forecast.
The expected earnings per share of Ganfeng Lithium Co., Ltd. for this year is forecasted to be 1.85 RMB/2.07 HKD.
OCBC published a research report stating that it maintains a "buy" rating for Ganfeng Lithium Group (01772), with a forecasted P/E ratio of 40 times and a 20% discount for H shares compared to A shares. The target price for H shares is raised significantly from 39 HKD to 83 HKD, and the target price for A shares of Ganfeng Lithium Group (002460.SZ) is raised from 45 CNY to 92 CNY.
Ganfeng Lithium Group is expected to have a net profit of between 1.1 billion to 1.65 billion CNY in 2025. The bank anticipates that lithium prices will remain high until the mining permit for the Jiangxi lithium mine is obtained, and believes that the profitability of the lithium industry will rebound in 2026. The bank has raised its earnings forecast for Ganfeng Lithium Group for this year to 1.85 CNY/2.07 HKD per share, supported by rising lithium product prices and profit margins, expanding contributions from battery and energy storage businesses, and investment income.
Related Articles

HK Stock Market Move | AI big model concept stocks performed well, with MINIMAX-WP (00100) skyrocketing by 15% and KNOWLEDGE ATLAS (02513) rising by nearly 7%.

HK Stock Market Move | Automobile stocks generally fell, Xpeng-W (09868) plunged over 9%, and the differentiation of January car sales by enterprises is evident.

HK Stock Market Move | CSPC PHARMA (01093) rose over 5% in early trading, following a major collaboration agreement with AstraZeneca. The company's external authorizations continue to be realized.
HK Stock Market Move | AI big model concept stocks performed well, with MINIMAX-WP (00100) skyrocketing by 15% and KNOWLEDGE ATLAS (02513) rising by nearly 7%.

HK Stock Market Move | Automobile stocks generally fell, Xpeng-W (09868) plunged over 9%, and the differentiation of January car sales by enterprises is evident.

HK Stock Market Move | CSPC PHARMA (01093) rose over 5% in early trading, following a major collaboration agreement with AstraZeneca. The company's external authorizations continue to be realized.

RECOMMEND

Multiple A‑Share Companies Update Hong Kong IPO Progress Since Start Of Year
30/01/2026

Mainland Pharmaceutical Companies Rush To Hong Kong, Over 10 Firms Queue For IPO
30/01/2026

2026 Hong Kong Market Faces Unlocking Peak: HKD 1.6 Trillion In Restricted Shares To Be Released, How Will The Market Respond?
30/01/2026


